Piramal Pharma Ltd (PPLPHARMA) — Board Meeting | 30 September 2026 (2 announcements)

30 September 2026 · BSE 🟡 Notable Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

1Board Meeting🟡 Notable Neutral📄 PDF

📢 Key Event

Board approves Brian Guy as new President and COO effective 19 October 2026

🔄 What Changed

Appointment of Brian Guy as new President and COO; retirement of Jeffrey Hampton

🔮 What's Next

Mr. Brian Guy will leverage his experience to drive accelerated growth and expansion of the Company’s Complex Hospital Generics business

💡 Investor Takeaway

Routine procedural filing with no direct impact on shareholders.

Piramal Pharma announced the retirement of President and COO Jeffrey Hampton effective 27 November 2026, followed by the Board's approval of Brian Guy as his successor effective 19 October 2026, with Guy to lead the Complex Hospital Generics business.

2Board Meeting🟡 Notable Neutral📄 PDF

📢 Key Event

Board approves appointment of Viral Gandhi as CTO and Senior Management Personnel effective 1 Oct 2026

🔄 What Changed

New CTO appointment adds technology leadership to drive digital transformation across Piramal Group operations

🔮 What's Next

None

💡 Investor Takeaway

Investors should monitor how this tech leadership addition may accelerate digital initiatives and impact operational efficiency and future growth prospects

Piramal Pharma announced the appointment of Viral Gandhi as Chief Technology Officer and Senior Management Personnel effective 1 October 2026, following board approval based on the Nomination and Remuneration Committee's recommendation. His background includes leading digital transformation at Piramal Group and prior roles at Cox & Kings and TCS, with advanced degrees from Harvard and MIT.

📊 Stock Analysis — PPLPHARMA ✨ Ask AI About This

About Piramal Pharma Ltd (PPLPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹27,465.71 CrROE: -3.8%ROCE: 1.7%

View full PPLPHARMA stock details →

📡 Get AI alerts when PPLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track PPLPHARMA — Free

💡 Ask AI about this filing

"How does Brian Guy's background align with Piramal's growth strategy?""What is the expected timeline for Complex Hospital Generics expansion?""How will leadership change affect stock valuation?"

Ask AI Free →

📊 More PPLPHARMA filings

Announcement — 1 October 2026Piramal Pharma clarified that Ontario's $1.7 million investment under the Life Sciences Scale-Up Fun...
🔴 Announcement — 1 October 2026Piramal Pharma disclosed that its commercial arrangement with Bayer Pharmaceuticals Private Limited,...
🔴 Corporate Action — 29 September 2026Piramal Pharma disclosed a GST audit order requiring Rs. 4,06,03,220 in input tax credit demand and ...
Announcement — 29 September 2026Piramal Pharma announced that its trading window will close on October 1, 2026, and remain shut for ...
🔴 Announcement — 18 September 2026Piramal Pharma disclosed that an independent ESG rating agency, Niche99, assigned it an ESG score of...

See all PPLPHARMA filings →

🔥 Also filed on 30 September 2026

544150KP Green Engineering LtdAnnouncement NINSYSNINtec Systems LtdAnnouncement ELANDE-Land Apparel LtdAnnouncement MOTILALOFSMotilal Oswal Financial Services LtdCorporate Action BANKINDIABank of IndiaAnnouncement SUNFLAGSunflag Iron & Steel Company LtdAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when PPLPHARMA files new disclosures

Track PPLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.